3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally

A hantavirus outbreak on a cruise ship sparked a biotech rally, but the article argues investors should avoid jumping in. The hantavirus is less contagious than COVID-19 and unlikely to become a global pandemic, limiting vaccine market potential. Even if it does spread widely, predicting which companies will succeed is nearly impossible, as demonstrated by COVID-19 vaccine developers. Better opportunities exist in established vaccine makers with strong pipelines or broad market index funds.

05/13/2026, 1:15 PM • The Motley Fool

Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells

The longevity biotech market is expanding rapidly, projected to grow from $9.86 billion in 2025 to $29.7 billion by 2034. Multiple companies are advancing cell and gene therapies targeting age-related diseases: Lineage Cell Therapeutics is developing islet therapy for Type 1 diabetes, Ocugen reported 46% lesion reduction in age-related macular degeneration, Vertex is advancing stem cell-derived islet therapy toward regulatory submissions, and Longeveron published positive Phase 2b data for age-related frailty treatment.

04/10/2026, 9:55 AM • Benzinga

Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data

Ocugen announced a webcast on January 15, 2026 to discuss Phase 2 clinical trial data from the OCU410 ArMaDa trial, featuring leading ophthalmologists and company executives. The presentation will cover one-year follow-up data from the first half of patients treated with the modifier gene therapy for blindness diseases.

01/13/2026, 7:00 AM • GlobeNewswire

Gene Therapy for Ocular Rare Disease Market to Exhibit Phenomenal Growth During the Forecast Period (2025–2034) Due to Expanding Pipeline and Clinical Trial Activities | DelveInsight

The gene therapy market for ocular rare diseases is expanding rapidly, with breakthrough viral vector technologies enabling one-time, disease-modifying treatments for inherited retinal disorders. Multiple emerging therapies are expected to transform treatment options for previously untreatable eye conditions.

11/19/2025, 1:00 PM • GlobeNewswire

Why Ocugen Stock Zoomed 12% Higher Today

Ocugen announced a licensing agreement with Kwangdong Pharmaceutical for OCU400, an investigational drug targeting retinitis pigmentosa, potentially earning up to $7.5 million upfront and future royalties of 25% on net sales in South Korea.

09/15/2025, 7:04 PM • The Motley Fool

Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

Ocugen, a biotechnology company focused on gene therapies for blindness diseases, closed a $20 million registered direct offering with Janus Henderson Investors, selling 20 million shares and warrants at $1.00 per share.

08/12/2025, 3:45 PM • GlobeNewswire

Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants

Ocugen has entered into a securities purchase agreement with Janus Henderson Investors to sell 20 million shares of common stock and warrants at $1.00 per share, expecting to raise approximately $20 million in gross proceeds.

08/08/2025, 5:03 PM • GlobeNewswire

AAV for the Hereditary Retinal Diseases Clinical Trial Pipeline Analysis Demonstrates 70+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight

A comprehensive analysis reveals over 70 companies developing AAV gene therapies for hereditary retinal diseases, offering potential transformative treatments for vision restoration through advanced gene therapy techniques.

08/05/2025, 1:00 PM • GlobeNewswire

Ocugen (OCGN) Shares Slide Following Merger Agreement: What's Going On?

Ocugen's shares are trading lower after the company announced a definitive agreement to merge its subsidiary OrthoCellix with Carisma Therapeutics in an all-stock deal.

06/23/2025, 2:26 PM • Benzinga